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Background
The immune system is able to control the growth of many
types of cancers. Most tumors show infiltration by tumor
infiltrating lymphocytes, but tumors modulate the local
microenvironment by expressing immune-inhibitory
molecules. Blockade of immune checkpoints such as cyto-
toxic T-lymphocyte-associated antigen-4 (CTLA-4), pro-
grammed cell death-1 (PD-1), and programmed cell death
ligand-1 (PD-L1) has shown clinical activity in immune-
responsive tumors as well as those historically deemed
unresponsive to treatment. Durvalumab (MEDI4736) is a
selective, high affinity human IgG1 monoclonal antibody
(mAb) that blocks PD-L1 binding to PD-1 (IC50 0.1 nM)
and CD80 (IC50 0.04 nM). Tremelimumab is a selective
human IgG2 mAb inhibitor of CTLA-4 which promotes
T-cell activity through CTLA-4 inhibition. Both durvalu-
mab and tremelimumab have demonstrated acceptable
safety profiles and promising clinical activity as single
agents in multiple tumor types. Recent data suggest that
combined checkpoint inhibition may generate superior
antitumor activity versus monotherapy, resulting in higher,
deeper, and more durable response rates, which suggests
that dual inhibition may overcome barriers to immune
response in historically non-immune responsive tumors.
We describe an ongoing study assessing the safety and
antitumor activity of durvalumab in combination with
tremelimumab in patients with advanced solid tumors.
Methods
This is a Phase I, multicenter, open-label, dose-exploration
and dose-expansion study in patients with select advanced
solid tumors (NCT02261220). Eligible patients (≥18 years)
will have recurrent or metastatic (R/M) disease and may
have been previously treated in the R/M setting. The
primary objective of this study is to assess the safety and
tolerability, and maximum tolerated dose of durvalumab
in combination with tremelimumab. The secondary objec-
tives are to assess antitumor activity (including overall
response rate, disease control rate, duration of response,
progression-free survival, and overall survival), pharmaco-
kinetics, pharmacodynamics, and immunogenicity of the
combination. Exploratory objectives will include an assess-
ment of biomarkers that may correlate with clinical activ-
ity of durvalumab in combination with tremelimumab.
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